Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biohaven’s Non-Migraine Portfolio Takes Another Hit As Verdiperstat Fails In ALS

Sep 29 2022

• By Alaric DeArment

Related Content

ICER Pushes ALS Drug Makers To Moderate Launch Price While Awaiting Confirmatory Data

Sep 13 2022

Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start

May 23 2022

Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase

May 10 2022

AstraZeneca's Ultomiris Disappoints In ALS, Setting Back Rare Disease Ambitions

Aug 20 2021

Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

Sep 27 2021

AbbVie Ready To Leverage Migraine Franchise In Crowded Market

Sep 30 2021

Related Companies

Biohaven Pharmaceutical Holding Company Ltd.

Pfizer Inc.

UCB S.A.

Clene, Inc.

Seelos Therapeutics, Inc.

Amylyx Pharmaceuticals, Inc.

AstraZeneca PLC

Additional Topics

Clinical Trials Deals Research & Development Neurology BioPharmaceutical

More from Neurological

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window